Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351143
Status:
COMPLETED
Last Update Posted:
2017-09-11
First Post:
2006-07-11
Brief Title:
A Comparative Study To Determine If Motivating Asthma Education Compliance Enhancement Has An Effect On Asthma Control
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50250 mcg bid Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate whether study subjects with previously uncontrolled asthma treated with SERETIDE Diskus 50250 CCI18781GR33343 mcg twice a day can attain a level of Total Control of their condition and whether adherence to treatment can be enhanced by teaching the subjects Two groups of equal size with identical medical treatment will be compared with each other the test group receiving three training modules during study visits and the control group regular study visits only
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None